High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Clinicians can encounter sex and gender disparities in diagnostic and therapeutic
responses. These disparities are noted in epidemiology, pathophysiology, clinical …

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Sex bias exists in the development and progression of nonreproductive organ cancers, but
the underlying mechanisms are enigmatic. Studies so far have focused largely on sexual …

The primary endpoint of MOUSEION-01 was to assess overall survival (OS) in male and
female patients receiving immune checkpoint inhibitors versus control treatments …

ECOG performance status (PS) is a pivotal prognostic factor in a wide number of solid
tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in …

Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …

The goal of sex and gender analysis is to promote rigorous, reproducible and responsible
science. Incorporating sex and gender analysis into experimental design has enabled …